Background: Most studies agreed that patients with inflammatory bowel disease are more likely to develop non-alcoholic fatty liver disease because of the presence of chronic infections, toxic drugs and altered gut microbiota.
Objectives: To evaluate and estimate the relationship between NAFLD and IBD and to discover the most important causes and risk factors among IBD patients.
Patients and methods: The study was done on a sample of (200) Egyptian cases diagnosed with inflammatory bowel disease. The criteria for including patients in this study included proving the disease through clinical examination, laboratory tests, imaging, and performing all necessary examinations for patients within this study. Patients with chronic viral hepatitis (B and C) as well as patients with hepatocellular carcinoma and all other liver diseases were excluded from this study because they affect the measure of liver stiffness.
Results: The mean age of all studied patients was 36.2 ± 6.2 years, 108 were females (54%), 37 patients were diabetic (18.5%), the mean BMI of all studied patients was 27.4 ± 3.3 kg/m². The prevalence of NAFLD between IBD patients was 36%. The mean liver stiffness measurement (LSM) of patients was 6.8 ± 3.6, the mean controlled attenuation parameter (CAP) was 223.5 ± 67.9.Risk factors responsible for the occurrence of NAFLD between IBD patients included DM, Insulin resistance, high anthropometric findings and dyslipidemia.
Conclusion: NAFLD is a common and recurrent disease in IBD patients. DM, Insulin resistance, high anthropometric findings and dyslipidemia are most important risk factors for occurrence of NAFLD between IBD patients.